RSS Feeds
Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure
- Mark B. McClellan, MD, PhD;
- Jerod M. Loeb, PhD;
- Carolyn M. Clancy, MD;
- Gary S. Francis, MD;
- Alice K. Jacobs, MD;
- Kenneth W. Kizer, MD, MPH;
- Margaret E. O'Kane; and
- Michael J. Wolk, MD
- From Centers for Medicare & Medicaid Services, Baltimore, MD 21244-1850; Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL 60181; Agency for Healthcare Research and Quality, Rockville, MD 20850; Heart Failure Society of America, Saint Paul, MN 55114; American Heart Association, Dallas, TX 75231; National Quality Forum, Washington, DC 20005; National Committee for Quality Assurance; Washington, DC 20036; and American College of Cardiology, Bethesda, MD 20814-1699.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITORS:
As noted in Lee and colleagues' meta-analysis (1), the evidence for use of angiotensin-receptor blockers (ARBs) for chronic heart failure and acute myocardial infarction (MI) with left ventricular systolic dysfunction has evolved, and relevant performance measures now need to …
